Long non‑coding RNA heart and neural crest derivatives expressed 2‑antisense RNA 1 overexpression inhibits the proliferation of cancer cells by reducing RUNX2 expression in triple‑negative breast cancer

Wei,Min; Liu,Lei; Wang,Zhiwei

doi:10.3892/ol.2019.11001

Long non‑coding RNA heart and neural crest derivatives expressed 2‑antisense RNA 1 overexpression inhibits the proliferation of cancer cells by reducing RUNX2 expression in triple‑negative breast cancer

Authors:
- Min Wei
- Lei Liu
- Zhiwei Wang
View Affiliations

Affiliations: Department of Breast, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University, Shanghai 200030, P.R. China, Department of Surgery, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu 226006, P.R. China
Published online on: October 18, 2019 https://doi.org/10.3892/ol.2019.11001
Pages: 6775-6780

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of long non‑coding RNA heart and neural crest derivatives expressed 2‑antisense RNA 1 (lncRNA HAND2‑AS1) in tumor suppression has been reported in a number of cancer types, while its functionality in triple‑negative breast cancer (TNBC) remains unclear. The present study aimed to investigate the involvement of lncRNA HAND2‑AS1 in TNBC using different methodologies. HAND2‑AS1 and RUNX2 expression was analyzed using reverse transcription‑quantitative PCR and western blot analysis. Diagnostic analysis was performed using receiver operating characteristic curve. Overexpression experiments were performed to analyze the interaction between HAND2‑AS1 and RUNX2 while the Cell Counting Kit‑8 assay was performed to analyze cell proliferation. In patients with early‑stage TNBC, the expression level of lncRNA HAND2‑AS1 was downregulated, whilst runt‑related transcription factor 2 (RUNX2) mRNA was upregulated in tumor tissues, compared with paired healthy tissues. Expression levels of lncRNA HAND2‑AS1 and RUNX2 mRNA were inversely correlated in tumor tissues, but not in paired healthy tissues. Decreased plasma expression levels of lncRNA HAND2‑AS1 were observed in TNBC patients compared with those in healthy controls, and the downregulation of lncRNA HAND2‑AS1 distinguished patients with TNBC from healthy controls. lncRNA HAND2‑AS1 overexpression inhibited RUNX2 expression, whilst RUNX2 overexpression did not significantly affect lncRNA HAND2‑AS1 expression in the MDA‑MB‑231 and BT‑20 cell lines. lncRNA HAND2‑AS1 overexpression resulted in the inhibition of cell proliferation, while RUNX2 overexpression promoted the proliferation of TNBC cells. RUNX2 overexpression partially reversed the effects of lncRNA HAND2‑AS1 overexpression on cancer cells. Therefore lncRNA HAND2‑AS1 may inhibit the proliferation of cancer cells by inhibiting RUNX2 expression in TNBC.

View Figures

View References

1	Zubeda S, Kaipa PR, Shaik NA, Mohiuddin MK, Vaidya S, Pavani B, Srinivasulu M, Latha MM and Hasan Q: Her-2/neu status: A neglected marker of prognostication and management of breast cancer patients in India. Asian Pac J Cancer Prev. 14:2231–2235. 2013. View Article : Google Scholar : PubMed/NCBI
2	Podo F, Buydens L, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, et al: Triple-negative breast cancer: Present challenges and new perspectives. Mol Oncol. 4:209–229. 2010. View Article : Google Scholar : PubMed/NCBI
3	Zhang W, Wan YW, Allen GI, Pang K, Anderson ML and Liu Z: Molecular pathway identification using biological network-regularized logistic models. BMC Genomics. 14 (Suppl 8):S72013. View Article : Google Scholar
4	Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME and Pietenpol JA: Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLoS One. 11:e01573682016. View Article : Google Scholar : PubMed/NCBI
5	Collignon J, Lousberg L, Schroeder H and Jerusalem G: Triple-negative breast cancer: Treatment challenges and solutions. Breast Cancer (Dove Med Press). 8:93–107. 2016.PubMed/NCBI
6	Denkert C, Liedtke C, Tutt A and von Minckwitz G: Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 389:2430–2442. 2017. View Article : Google Scholar : PubMed/NCBI
7	Mayer IA, Abramson VG, Lehmann BD and Pietenpol JA: New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clin Cancer Res. 20:782–790. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lucero CM, Vega OA, Osorio MM, Tapia JC, Antonelli M, Stein GS, van Wijnen AJ and Galindo MA: The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines. J Cell Physiol. 228:714–723. 2013. View Article : Google Scholar : PubMed/NCBI
9	Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB and Stein GS: Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA. 102:1454–1459. 2005. View Article : Google Scholar : PubMed/NCBI
10	Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS and Lian JB: Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res. 68:7795–7802. 2008. View Article : Google Scholar : PubMed/NCBI
11	Taipaleenmäki H, Browne G, Akech J, Zustin J, van Wijnen AJ, Stein JL, Hesse E, Stein GS and Lian JB: Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 75:1433–1444. 2015. View Article : Google Scholar : PubMed/NCBI
12	Chai J, Guo D, Ma W, Han D, Dong W, Guo H and Zhang Y: A feedback loop consisting of RUNX2/lncRNA-PVT1/miR-455 is involved in the progression of colorectal cancer. Am J Cancer Res. 8:538–550. 2018.PubMed/NCBI
13	Yu X, Zhao J and He Y: Long non-coding RNA PVT1 functions as an oncogene in human colon cancer through miR-30d-5p/RUNX2 axis. J BUON. 23:48–54. 2018.PubMed/NCBI
14	Kang Y, Zhu X, Xu Y, Tang Q, Huang Z, Zhao Z, Lu J, Song G, Xu H, Deng C and Wang J: Energy stress-induced lncRNA HAND2-AS1 represses HIF1α-mediated energy metabolism and inhibits osteosarcoma progression. Am J Cancer Res. 8:526–537. 2018.PubMed/NCBI
15	Zhou J, Lin J, Zhang H, Zhu F and Xie R: lncRNA HAND2-AS1 sponging miR-1275 suppresses colorectal cancer progression by upregulating KLF14. Biochem Biophys Res Commun. 503:1848–1853. 2018. View Article : Google Scholar : PubMed/NCBI
16	Yang X, Wang CC, Lee WYW, Trovik J, Chung TKH and Kwong J: Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U. Cancer Lett. 413:23–34. 2018. View Article : Google Scholar : PubMed/NCBI
17	Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ and Hortobagyi GN: Breast cancer-major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 67:290–303. 2017. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW and Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
20	Pratap J, Imbalzano KM, Underwood JM, Cohet N, Gokul K, Akech J, van Wijnen AJ, Stein JL, Imbalzano AN, Nickerson JA, et al: Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: Implications for breast cancer progression. Cancer Res. 69:6807–6814. 2009. View Article : Google Scholar : PubMed/NCBI
21	Sancisi V, Manzotti G, Gugnoni M, Rossi T, Gandolfi G, Gobbi G, Torricelli F, Catellani F, Faria do Valle I, Remondini D, et al: RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN. Nucleic Acids Res. 45:11249–11267. 2017. View Article : Google Scholar : PubMed/NCBI